New England Journal of Medicine February 14, 2019

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Gunter von Minckwitz, Chiun-Sheng Huang, Max S. Mano, et al.

Bottom Line

In patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant therapy, adjuvant treatment with trastuzumab emtansine (T-DM1) significantly reduces the risk of invasive recurrence or death compared to standard trastuzumab.

Key Findings

1. At a median follow-up of 41.4 months, invasive disease or death occurred in 12.2% (91 of 743) of patients receiving T-DM1 compared to 22.2% (165 of 743) of patients receiving trastuzumab.

2. Adjuvant T-DM1 significantly improved invasive disease-free survival (iDFS) over trastuzumab, demonstrating a hazard ratio of 0.50 (95% CI, 0.39 to 0.64; P<0.001).

3. The estimated 3-year iDFS rate was 88.3% in the T-DM1 group versus 77.0% in the trastuzumab arm, representing an absolute improvement of 11.3 percentage points.

4. Distant recurrence as the first invasive-disease event was substantially lower with T-DM1 (10.5%) compared to trastuzumab (15.9%).

5. Adverse events of grade 3 or higher occurred more frequently in the T-DM1 group (25.7%) than in the trastuzumab group (15.4%), including thrombocytopenia and hypertension.

Study Design

Design

Phase 3 Randomized Controlled Trial

Open-Label

Sample

1,486

Patients

Duration

41.4 mo

Median

Setting

Multicenter, global

Population Patients with centrally confirmed HER2-positive early breast cancer who had residual invasive disease in the breast or axilla following at least 6 cycles of neoadjuvant chemotherapy (taxane-based) and at least 9 weeks of trastuzumab-based HER2-targeted therapy.

Intervention Trastuzumab emtansine (T-DM1) 3.6 mg/kg intravenously every 3 weeks for 14 cycles.

Comparator Trastuzumab 6 mg/kg intravenously every 3 weeks for 14 cycles.

Outcome Invasive disease-free survival (iDFS), defined as freedom from ipsilateral invasive breast tumor recurrence, ipsilateral locoregional invasive breast cancer recurrence, contralateral invasive breast cancer, distant recurrence, or death from any cause.

Study Limitations

• The open-label design introduces a potential for bias, although this is mitigated by the objective nature of major recurrence and survival endpoints.

• Overall survival (OS) data were immature at the time of this primary analysis, meaning a definitive mortality benefit was not yet established in the 2019 report (though confirmed in later updates).

• T-DM1 was associated with a higher incidence of toxicities, such as thrombocytopenia, elevated liver transaminases, and neuropathy, which led to more treatment discontinuations (18.0% vs. 2.1%).

• The findings are exclusively applicable to patients who undergo neoadjuvant therapy and have residual invasive disease; they do not apply to upfront surgery populations or those achieving a pathologic complete response.

Clinical Significance

The KATHERINE trial was universally practice-changing. By halving the risk of recurrence, it established T-DM1 as the definitive standard-of-care adjuvant therapy for high-risk patients with HER2-positive breast cancer who fail to achieve a pathologic complete response after neoadjuvant taxane- and HER2-targeted therapy.

Historical Context

Prior to the KATHERINE trial, the standard of care for all patients with early-stage HER2-positive breast cancer was to complete exactly one year of trastuzumab therapy (with or without pertuzumab) post-surgery, regardless of their tumor's pathological response to neoadjuvant treatment. It was well known that patients who had residual invasive disease at the time of surgery harbored a significantly higher risk of systemic recurrence and death than those achieving a pathologic complete response (pCR). The KATHERINE trial pioneered 'response-guided therapy' in the HER2-positive setting, demonstrating that switching the post-operative regimen to the antibody-drug conjugate T-DM1 for those without a pCR could rescue these high-risk patients and dramatically alter their disease trajectory.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

How does the mechanism of action of trastuzumab emtansine (T-DM1) differ from standard trastuzumab, and why is this advantageous for residual disease?

Key Response

T-DM1 is an antibody-drug conjugate linking a HER2-targeted antibody to a microtubule inhibitor (DM1). Unlike trastuzumab, which mainly blocks signaling and mediates ADCC, T-DM1 internalizes and delivers a cytotoxic payload directly into HER2-expressing cells, helping overcome resistance mechanisms that allowed the cells to survive neoadjuvant trastuzumab.

Resident

Based on the KATHERINE trial, what are the exact clinical criteria for using adjuvant T-DM1, and what distinct toxicities must be monitored compared to trastuzumab alone?

Key Response

T-DM1 is indicated for patients with HER2-positive early breast cancer who have residual invasive disease (non-pCR) in the breast or axilla after neoadjuvant taxane and trastuzumab-based therapy. Clinicians must monitor for T-DM1-specific toxicities driven by the DM1 payload, including thrombocytopenia, transaminitis, and peripheral neuropathy, which differ from the classic cardiotoxicity of trastuzumab.

Fellow

The KATHERINE trial demonstrated a profound iDFS benefit, but did it reduce the incidence of CNS recurrences? How should this influence systemic strategy for high-risk HER2-positive patients?

Key Response

The incidence of CNS recurrences was similar between the T-DM1 and trastuzumab arms (approximately 4-5%), indicating that while T-DM1 provides excellent systemic disease control, it does not cross the blood-brain barrier sufficiently to prevent CNS metastases. Fellows must recognize the CNS as a sanctuary site in HER2-positive disease, highlighting the need for vigilance and future integration of CNS-penetrant TKIs like tucatinib.

Attending

How does the KATHERINE trial solidify the paradigm of using neoadjuvant therapy as an in vivo biomarker, and how do you counsel patients on the efficacy-toxicity trade-offs of escalating therapy?

Key Response

The trial established that achieving a pathologic complete response (pCR) or lack thereof should dictate adjuvant therapy, shifting the field to an 'escalation for residual disease' model. Attendings should teach that neoadjuvant therapy assesses tumor biology in real time. Counseling requires weighing the absolute 11.3 percent improvement in 3-year iDFS against the higher risk of Grade 3 or higher adverse events like neuropathy and cytopenias with T-DM1.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The KATHERINE trial used invasive disease-free survival (iDFS) as its primary endpoint. Methodologically, what are the statistical implications and potential confounding factors of relying on iDFS instead of overall survival in early-stage breast cancer trials?

Key Response

iDFS accelerates trial readouts and regulatory approvals since overall survival (OS) events in early breast cancer take years to accumulate. However, iDFS is a composite endpoint (local, regional, distant recurrences, contralateral cancer, death) where some components may not perfectly surrogate for OS. A key methodological challenge is assessing whether the early iDFS magnitude holds true for OS, especially when post-recurrence crossover or salvage therapies extend survival.

Journal Editor

Considering the evolving landscape of HER2-positive breast cancer treatment during the KATHERINE trial's enrollment, what is a major limitation regarding the neoadjuvant regimens used, and how does this impact the trial's external validity?

Key Response

A critical peer reviewer would note that only about 18 percent of patients in the trial received dual HER2 blockade (trastuzumab plus pertuzumab) in the neoadjuvant setting, as it was just becoming the standard of care. This raises questions about external validity and whether T-DM1 maintains the same absolute magnitude of benefit in modern patients who have residual disease despite aggressive upfront dual blockade.

Guideline Committee

How do the results of the KATHERINE trial inform ASCO and NCCN guideline recommendations for the adjuvant treatment of HER2-positive breast cancer, and what level of evidence supports this practice shift?

Key Response

The KATHERINE trial provided Category 1, high-level evidence that prompted ASCO and NCCN to strongly recommend 14 cycles of adjuvant T-DM1 for patients with HER2-positive breast cancer who do not achieve a pCR after neoadjuvant targeted therapy. This fundamentally updated previous guidelines, which recommended continuing standard trastuzumab (with or without pertuzumab), thereby establishing T-DM1 as the definitive standard of care for residual disease.

Clinical Landscape

Noteworthy Related Trials

2012

EMILIA Trial

n = 991 · NEJM

Tested

Trastuzumab emtansine (T-DM1)

Population

HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane

Comparator

Lapatinib plus capecitabine

Endpoint

Progression-free survival and overall survival

Key result: T-DM1 significantly prolonged progression-free and overall survival with less toxicity compared to lapatinib plus capecitabine.

2012

NeoSphere Trial

n = 417 · Lancet Oncol

Tested

Pertuzumab plus trastuzumab and docetaxel

Population

Locally advanced, inflammatory, or early HER2-positive breast cancer

Comparator

Trastuzumab plus docetaxel

Endpoint

Pathological complete response (pCR) in the breast

Key result: Adding pertuzumab to trastuzumab and docetaxel significantly improved the pathological complete response rate.

2017

APHINITY Trial

n = 4,805 · NEJM

Tested

Pertuzumab plus trastuzumab and chemotherapy

Population

Node-positive or high-risk node-negative HER2-positive early breast cancer

Comparator

Placebo plus trastuzumab and chemotherapy

Endpoint

Invasive disease-free survival

Key result: The addition of pertuzumab to adjuvant trastuzumab and chemotherapy slightly but significantly improved invasive disease-free survival, particularly in node-positive patients.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis